Methods Of Enhancing And/Or Stabilizing Cardiac Function In Patients With Fabry Disease
Patent No. EP4176877 (titled "Methods Of Enhancing And/Or Stabilizing Cardiac Function In Patients With Fabry Disease") was filed by Amicus Therapeutics on Aug 28, 2018. The application was issued on Dec 4, 2024.
Patent Summary
Treatment of Fabry disease in patients who have previously received enzyme replacement therapy (ERT) using migalastat, a pharmacological chaperone that selectively stabilizes mutant forms of the lysosomal enzyme alpha-galactosidase A (α-Gal A). The treatment enhances cardiac function in patients with left ventricular hypertrophy, particularly in those with midwall fractional shortening (MWFS) values indicative of hypertensive target-organ damage. Migalastat is administered orally at a dose of 123 mg every other day, and its efficacy is demonstrated in patients with a range of Fabry disease severity, including those with primarily cardiac manifestations.
Patent Family
Patent Oppositions (3)
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
Get instant alerts for new documents
EP4176877
- Application Number
- EP22194251A
- Filing Date
- Aug 28, 2018
- Status
- Granted And Under Opposition
- Nov 1, 2024
- Publication Date
- Dec 4, 2024
- External Links
- Slate, Register , Google Patents